AU2021224232A1 - Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision - Google Patents

Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision Download PDF

Info

Publication number
AU2021224232A1
AU2021224232A1 AU2021224232A AU2021224232A AU2021224232A1 AU 2021224232 A1 AU2021224232 A1 AU 2021224232A1 AU 2021224232 A AU2021224232 A AU 2021224232A AU 2021224232 A AU2021224232 A AU 2021224232A AU 2021224232 A1 AU2021224232 A1 AU 2021224232A1
Authority
AU
Australia
Prior art keywords
use according
pharmaceutical composition
improvement
individual
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021224232A
Other languages
English (en)
Inventor
Mohammed DIBAS
Massoud Fahid
Richard Graham
Ke Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2021224232A1 publication Critical patent/AU2021224232A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021224232A 2020-02-20 2021-02-19 Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision Abandoned AU2021224232A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062979214P 2020-02-20 2020-02-20
US62/979,214 2020-02-20
PCT/US2021/018906 WO2021168349A1 (en) 2020-02-20 2021-02-19 Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision

Publications (1)

Publication Number Publication Date
AU2021224232A1 true AU2021224232A1 (en) 2022-10-13

Family

ID=74875311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021224232A Abandoned AU2021224232A1 (en) 2020-02-20 2021-02-19 Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision

Country Status (12)

Country Link
US (2) US20210260041A1 (https=)
EP (1) EP4106728A1 (https=)
JP (1) JP2023514732A (https=)
KR (1) KR20220157392A (https=)
CN (1) CN115443125A (https=)
AU (1) AU2021224232A1 (https=)
BR (1) BR112022016730A2 (https=)
CA (1) CA3168767A1 (https=)
IL (1) IL295782A (https=)
MX (1) MX2022010317A (https=)
TW (1) TW202139998A (https=)
WO (1) WO2021168349A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
WO2014159576A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
EP2978406A1 (en) 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途

Also Published As

Publication number Publication date
EP4106728A1 (en) 2022-12-28
MX2022010317A (es) 2023-01-24
CA3168767A1 (en) 2021-08-26
US20210260041A1 (en) 2021-08-26
BR112022016730A2 (pt) 2022-11-08
TW202139998A (zh) 2021-11-01
JP2023514732A (ja) 2023-04-07
KR20220157392A (ko) 2022-11-29
US20240335425A1 (en) 2024-10-10
CN115443125A (zh) 2022-12-06
WO2021168349A1 (en) 2021-08-26
IL295782A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
JP7470667B2 (ja) 眼の状態の治療のためのピロカルピン塩酸塩の使用
KR102472774B1 (ko) 안과용 약학 조성물 및 이와 관련된 용도
US20240358682A1 (en) Use of alpha-2-adrenergic receptor agonists for improving vision
US20240390330A1 (en) Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes
US20240335425A1 (en) Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision
US11077053B2 (en) Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
HK40053072A (en) The use of alpha-2-adrenergic receptor agonists for improving vision
HK40034331B (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
HK40034331A (en) Use of pilocarpine hydrochloride for the treatment of presbyopia

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period